Table 1.
Demographics and baseline characteristics
| Characteristic | Model 1 (N=1,592)a | Model 2 (N=374)b | Models 3 and 4 (N=1,218)c | |
|---|---|---|---|---|
| Age at first neurologic assessment | 10–19 | 8 (1 %) | 1 (0 %) | 7 (1 %) |
| 20–29 | 267 (17 %) | 42 (11 %) | 225 (18 %) | |
| 30–39 | 670 (42 %) | 114 (30 %) | 556 (46 %) | |
| 40–49 | 475 (30 %) | 144 (39 %) | 331 (27 %) | |
| 50–59 | 139 (9 %) | 52 (14 %) | 87 (7 %) | |
| Over 60 | 33 (2 %) | 21 (6 %) | 12 (1 %) | |
| Sex | Male | 1,280 (80 %) | 298 (80 %) | 982 (81 %) |
| Female | 312 (20 %) | 76 (20 %) | 236 (19 %) | |
| Race | Other | 37 (2 %) | 80 (21 %) | 293 (24 %) |
| Hispanic | 336 (21 %) | N/A | N/A | |
| Black | 502 (32 %) | 135 (36 %) | 367 (30 %) | |
| White | 717 (45 %) | 159 (43 %) | 558 (46 %) | |
| IV Drug history | No | 1,466 (92 %) | 332 (89 %) | 1,134 (93 %) |
| Yes | 126 (8 %) | 42 (11 %) | 84 (7 %) | |
| HCV seropositivity | Positive ever | 161 (10 %) | 50 (13 %) | 111 (9 %) |
| Negative | 1,431 (90 %) | 324 (87 %) | 1,107 (91 %) | |
| Pre-ART CD4 (cells/μL) | Number | 1,592 | 374 | 1,218 |
| Mean (s.d.) | 239 (196) | 214 (192) | 247 (197) | |
| Median | 213 | 166 | 224 | |
| Q1, Q3 | 68, 351 | 50, 324 | 76, 362 | |
| Pre-ART log10 (HIV RNA), (cp/mL) | Number | 1,592 | 374 | 1,218 |
| Mean (s.d.) | 4.92 (0.75) | 5.00 (0.73) | 4.90 (0.76) | |
| Median | 4.87 | 4.91 | 4.85 | |
| Q1, Q3 | 4.44, 5.46 | 4.48, 5.58 | 4.43, 5.43 |
s.d. standard deviation
a
Model 1 = APN risk factor for future SPN
b
Model 2 = Risk factors for SPN from APN
c
Models 3 and 4 = Risk factors for APN and SPN from no PN